SCHEMBL1979596

SCHEMBL1979596

Cc1cccc(Oc2ccc([N+](=O)[O-])cc2)c1C

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSPB1 P04792 3/20 0.53
ALDH1A1 P00352 5/20 0.50
TP53 P04637 1/20 0.50
HTT P42858 1/20 0.49
DHFR P00374 1/20 0.48
TSHR P16473 1/20 0.47
SMN1; SMN2 Q16637 1/20 0.47
MEN1 O00255 3/20 0.47
KMT2A Q03164 3/20 0.47
RXFP1 Q9HBX9 1/20 0.47
KDM4E B2RXH2 1/20 0.46
POLB P06746 1/20 0.45
GAA P10253 1/20 0.45
CRHBP P24387 1/20 0.45
FNTA P49354 1/20 0.45
FNTB P49356 1/20 0.45
CRHR2 Q13324 1/20 0.45
ACHE P22303 1/20 0.44
HSD17B10 Q99714 1/20 0.44
ATM Q13315 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4378038 0.87 HSPB1 (0.56) HSPB1ALDH1A1HTTTSHRSMN1; SMN2
SCHEMBL1584226 0.84 HSPB1 (0.50) HSPB1ALDH1A1HTTMEN1KMT2A
SCHEMBL24576257 0.82 DHFR (0.62) ALDH1A1TP53HTTDHFRSMN1; SMN2
SCHEMBL31448160 0.81 HSPB1 (0.53) HSPB1ALDH1A1TP53HTTTSHR
SCHEMBL7632959 0.81 HSPB1 (0.66) HSPB1ALDH1A1HTTSMN1; SMN2MEN1
SCHEMBL31448182 0.79 HTT (0.51) HSPB1ALDH1A1HTTTSHRMEN1
SCHEMBL1978695 0.78 KEAP1 (0.59) HSPB1ALDH1A1TP53HTTSMN1; SMN2
SCHEMBL10515697 0.78 ALDH1A1 (0.53) HSPB1ALDH1A1HTTSMN1; SMN2MEN1
SCHEMBL8043805 0.77 HSPB1 (0.53) HSPB1ALDH1A1HTTSMN1; SMN2MEN1
SCHEMBL11585245 0.77 DHFR (0.57) ALDH1A1HTTDHFRSMN1; SMN2MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20200163964-A1 IMIDAZOLIDINEDIONE DERIVATIVES AUTIFONY THERAPEUTICS LIMITED (GB) 2020-05-28 US disclosed
US-20200163964-A1 IMIDAZOLIDINEDIONE DERIVATIVES AUTIFONY THERAPEUTICS LIMITED (GB) 2020-05-28 US disclosed
US-10632118-B2 Imidazolidinedione derivatives AUTIFONY THERAPEUTICS LIMITED (GB) 2020-04-28 US disclosed
US-10632118-B2 Imidazolidinedione derivatives AUTIFONY THERAPEUTICS LIMITED (GB) 2020-04-28 US disclosed
US-20180338974-A1 IMIDAZOLIDINEDIONE DERIVATIVES AUTIFONY THERAPEUTICS LIMITED (GB) 2018-11-29 US disclosed
US-10058551-B2 Imidazolidinedione derivatives AUTIFONY THERAPEUTICS LIMITED (GB) 2018-08-28 US disclosed
US-20180021336-A1 IMIDAZOLIDINEDIONE DERIVATIVES AUTIFONY THERAPEUTICS LIMITED (GB) 2018-01-25 US disclosed
US-20180021336-A1 IMIDAZOLIDINEDIONE DERIVATIVES AUTIFONY THERAPEUTICS LIMITED (GB) 2018-01-25 US disclosed
US-20180021336-A1 IMIDAZOLIDINEDIONE DERIVATIVES AUTIFONY THERAPEUTICS LIMITED (GB) 2018-01-25 US disclosed
US-9849131-B2 Imidazolidinedione derivatives AUTIFONY THERAPEUTICS LIMITED (GB) 2017-12-26 US disclosed
US-9216967-B2 Imidazolidinedione derivatives AUTIFONY THERAPEUTICS LIMITED (GB) 2015-12-22 US disclosed
US-8722695-B2 Imidazolidinedione derivatives AUTIFONY THERAPEUTICS LIMITED (GB) 2014-05-13 US disclosed
US-8722695-B2 Imidazolidinedione derivatives AUTIFONY THERAPEUTICS LIMITED (GB) 2014-05-13 US disclosed
US-8722695-B2 Imidazolidinedione derivatives AUTIFONY THERAPEUTICS LIMITED (GB) 2014-05-13 US disclosed
US-20120289526-A1 IMIDAZOLIDINEDIONE DERIVATIVES AUTIFONY THERAPEUTICS LIMITED (GB) 2012-11-15 US disclosed
US-20120289526-A1 IMIDAZOLIDINEDIONE DERIVATIVES AUTIFONY THERAPEUTICS LIMITED (GB) 2012-11-15 US disclosed
US-20120289526-A1 IMIDAZOLIDINEDIONE DERIVATIVES AUTIFONY THERAPEUTICS LIMITED (GB) 2012-11-15 US disclosed
EP-2509961-A1 IMIDAZOLIDINEDIONE DERIVATIVES Autifony Therapeutics Limited (GB) 2012-10-17 EP disclosed
WO-2011069951-A1 IMIDAZOLIDINEDIONE DERIVATIVES GLAXO GROUP LIMITED (GB) 2011-06-16 WO disclosed
WO-2011069951-A1 IMIDAZOLIDINEDIONE DERIVATIVES GLAXO GROUP LIMITED (GB) 2011-06-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180338974-A1 IMIDAZOLIDINEDIONE DERIVATIVES KCND3, KCNK3, KCNA3 HSPB1 4360/4885ALDH1A1 848/4885TP53 4879/4885
US-20180021336-A1 IMIDAZOLIDINEDIONE DERIVATIVES KCND3, KCNK3, KCNA3 HSPB1 4360/4885ALDH1A1 848/4885TP53 4879/4885
US-10632118-B2 Imidazolidinedione derivatives KCND3, KCNK3, KCNA3 HSPB1 4360/4885ALDH1A1 848/4885TP53 4879/4885
US-10058551-B2 Imidazolidinedione derivatives KCND3, KCNK3, KCNA3 HSPB1 4360/4885ALDH1A1 848/4885TP53 4879/4885
US-20200163964-A1 IMIDAZOLIDINEDIONE DERIVATIVES KCND3, KCNK3, KCNA3 HSPB1 4360/4885ALDH1A1 848/4885TP53 4879/4885
US-20120289526-A1 IMIDAZOLIDINEDIONE DERIVATIVES KCND3, KCNK3, KCNA3 HSPB1 4599/4885ALDH1A1 462/4885TP53 4845/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.